CLEC3B

Across TCGA pan-cancer cohorts, CLEC3B mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CLEC3B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CLEC3B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CLEC3B is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and COAD are the cancer types where CLEC3B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLEC3B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	−1.271	<.001	11	view →
LUAD	Female	III,IV	−1.508	<.001	9	view →
COAD	Male	All	−0.870	<.001	9	view →
LSCC	Female	All	−1.400	<.001	8	view →
PDAC	Female	All	+0.873	<.001	6	view →
CCRCC	Male	III,IV	−0.493	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CLEC3B–HNSC

Open the HNSC breakdown →